{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:53:05Z","timestamp":1791604385233,"version":"4.3.4"},"reference-count":31,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,10,9]]},"DOI":"10.1253\/circrep.cr-26-0095","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:10:36Z","timestamp":1789078236000},"page":"1649-1657","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Diagnosis of Transthyretin Amyloidosis Cardiomyopathy in Japan\u3000\u2015 Care Pathway Barriers and Opportunities \u2015"],"prefix":"10.1253","volume":"8","author":[{"given":"Jin","family":"Endo","sequence":"first","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism, BioPharmaceuticals Medical, AstraZeneca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Tsubota","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism, BioPharmaceuticals Medical, AstraZeneca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Crawford","sequence":"additional","affiliation":[{"name":"Aquarius Population Health Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Hsu","sequence":"additional","affiliation":[{"name":"Aquarius Population Health Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. <i>Circ J<\/i> 2020; 84: 1610\u20131671, doi:10.1253\/circj.CJ-20-0110.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"2","unstructured":"2. Jain A, Zahra F. Transthyretin amyloid cardiomyopathy (ATTR-CM). <i>In<\/i>: StatPearls. StatPearls Publishing. 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574531\/ (accessed March 27, 2025)."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. <i>Circ Res<\/i> 2021; 128: 1554\u20131575, doi:10.1161\/CIRCRESAHA.121.318187.","DOI":"10.1161\/CIRCRESAHA.121.318187"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Naito T, Nakamura K, Abe Y, Watanabe H, Sakuragi S, Katayama Y, et al. Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan. <i>ESC Heart Fail<\/i> 2023; 10: 1896\u20131906, doi:10.1002\/ehf2.14364.","DOI":"10.1002\/ehf2.14364"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T, et al. Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. <i>Circ J<\/i> 2022; 86: 1121\u20131128, doi:10.1253\/circj.CJ-21-0965.","DOI":"10.1253\/circj.CJ-21-0965"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Yamada T, Takashio S, Arima Y, Nishi M, Morioka M, Hirakawa K, et al. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. <i>ESC Heart Fail<\/i> 2020; 7: 2829\u20132837, doi:10.1002\/ehf2.12884.","DOI":"10.1002\/ehf2.12884"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Takashio S, Tokitsu T, Matsukawa M, Sakaino N, Fujimoto K, Sakamoto T, et al. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey. <i>J Cardiol<\/i> 2022; 80: 49\u201355, doi:10.1016\/j.jjcc.2022.01.002.","DOI":"10.1016\/j.jjcc.2022.01.002"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Matsushima M, Tarisawa M, Nomura T, Oshima Y, Yoshino M, Shibata Y, et al. Practice of hereditary ATTR amyloidosis in non-endemic areas of Japan. <i>Intern Med<\/i> 2022; 62: 1599\u20131602, doi:10.2169\/internalmedicine.0091-22.","DOI":"10.2169\/internalmedicine.0091-22"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Ando Y, Waddington-Cruz M, Sekijima Y, Koike H, Ueda M, Konishi H, et al. Optimal practices for the management of hereditary transthyretin amyloidosis: Real-world experience from Japan, Brazil, and Portugal. <i>Orphanet J Rare Dis<\/i> 2023; 18: 323, doi:10.1186\/s13023-023-02910-3.","DOI":"10.1186\/s13023-023-02910-3"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): A targeted literature review. <i>Cardiol Ther<\/i> 2021; 10: 141\u2013159, doi:10.1007\/s40119-021-00219-5.","DOI":"10.1007\/s40119-021-00219-5"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Izumiya Y, Kubo T, Endo J, Takashio S, Minamisawa M, Hamada J, et al. Transthyretin amyloid cardiomyopathy: Literature review and red-flag symptom clusters for each cardiology specialty. <i>ESC Heart Fail<\/i> 2025; 12: 955\u2013967, doi:10.1002\/ehf2.15016.","DOI":"10.1002\/ehf2.15016"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Sekijima Y, Yazaki M, Ueda M, Koike H, Yamada M, Ando Y. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. <i>Amyloid<\/i> 2018; 25: 8\u201310, doi:10.1080\/13506129.2017.1409706.","DOI":"10.1080\/13506129.2017.1409706"},{"key":"13","unstructured":"13. Statistics Bureau of Japan. Current population estimates as of October 1, 2024. https:\/\/www.stat.go.jp\/english\/data\/jinsui\/2024np\/index.html (accessed January 12, 2026)."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Takashio S, Morioka M, Ishii M, Morikawa K, Hirakawa K, Hanatani S, et al. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy. <i>ESC Heart Fail<\/i> 2023; 10: 4, doi:10.1002\/ehf2.14380.","DOI":"10.1002\/ehf2.14380"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Yilmaz A, Bauersachs J, Bengel F, B\u00fcchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: Position statement of the German Cardiac Society (DGK). <i>Clin Res Cardiol<\/i> 2021; 110: 479\u2013506, doi:10.1007\/s00392-020-01799-3.","DOI":"10.1007\/s00392-020-01799-3"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Minamisawa M, Konishi H, Kitano Y, Abe H, Togo K, Izumiya Y. Patient journey from the appearance of red flags to the diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) in Japan: A nationwide retrospective study using a medical claims database. <i>Eur Heart J<\/i> 2024; 45(Supplement_1): ehae666.785, doi:10.1093\/eurheartj\/ehae666.785.","DOI":"10.1093\/eurheartj\/ehae666.785"},{"key":"17","unstructured":"17. Japanese Circulation Society. Certification application requirements: Application guidelines for facility certification and physician certification for disease-modifying drug introduction for transthyretin-type cardiac amyloidosis [in Japanese]. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2025\/06\/\u75be\u60a3\u4fee\u98fe\u85ac\u5c0e\u5165\u65bd\u8a2d\u304a\u3088\u3073\u533b\u5e2b\u8a8d\u5b9a\u7533\u8acb\u8981\u9805_20250625.pdf (accessed July 18, 2025)."},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Ueda M, Sekijima Y, Koike H, Yamashita T, Yoshinaga T, Ishii T, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. <i>J Neurol Sci<\/i> 2020; 414: 116813, doi:10.1016\/j.jns.2020.116813.","DOI":"10.1016\/j.jns.2020.116813"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Winburn I, Ishii T, Sumikawa T, Togo K, Yasunaga H. Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan. <i>Cardiol Ther<\/i> 2019; 8: 297\u2013316, doi:10.1007\/s40119-019-0142-5.","DOI":"10.1007\/s40119-019-0142-5"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, et al. A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2019; 84: 15\u201317, doi:10.1253\/circj.CJ-19-0811.","DOI":"10.1253\/circj.CJ-19-0811"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Minamisawa M, Konishi H, Kitano Y, Abe H, Togo K, Izumiya Y. Patient journey to transthyretin cardiac amyloidosis diagnosis: A Japanese claims database study. <i>Circ J<\/i> 2025; 89: 432\u2013441, doi:10.1253\/circj.CJ-24-0666.","DOI":"10.1253\/circj.CJ-24-0666"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Meiwald A, Gara-Adams R, Rowlandson A, Ma Y, Watz H, Ichinose M, et al. Qualitative validation of COPD evidenced care pathways in Japan, Canada, England, and Germany: Common barriers to optimal COPD care. <i>Int J Chron Obstruct Pulmon Dis<\/i> 2022; 17: 1507\u20131521, doi:10.2147\/COPD.S360983.","DOI":"10.2147\/COPD.S360983"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. <i>Int J Qual Health Care<\/i> 2007; 19: 349\u2013357, doi:10.1093\/intqhc\/mzm042.","DOI":"10.1093\/intqhc\/mzm042"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Vogel J, Jura S, Settelmeier S, Buehning F, Lerchner T, Carpinteiro A, et al. Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real-world data analysis. <i>ESC Heart Fail<\/i> 2025; 12: 2969\u20132975, doi:10.1002\/ehf2.15311.","DOI":"10.1002\/ehf2.15311"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Oghina S, Legallois D, Hyafil F, Amara W, Andr\u00e8s E, Bardin T, et al. Diagnostic pathway for cardiac amyloidosis from the healthcare professional\u2019s perspective: Results from the French DIAM-ATTR survey. <i>Ann Med<\/i> 2025; 57: 2525391, doi:10.1080\/07853890.2025.2525391.","DOI":"10.1080\/07853890.2025.2525391"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Kudo T, Kuji I, Nakajima K, Fukushima K, Maruno H, Iguchi N, et al. Nuclear medicine imaging for the diagnosis of ATTR cardiac amyloidosis. <i>Ann Nucl Cardiol<\/i> 2025; 11: 3\u201312, doi:10.17996\/anc.25-001.","DOI":"10.17996\/anc.25-001"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Baynam G, Gomez R, Jain R. Stigma associated with genetic testing for rare diseases: Causes and recommendations. <i>Front Genet<\/i> 2024; 15: 1335768, doi:10.3389\/fgene.2024.1335768.","DOI":"10.3389\/fgene.2024.1335768"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al. JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure. <i>J Card Fail<\/i> 2025; 31: 1164\u20131322, doi:10.1016\/j.cardfail.2025.02.014.","DOI":"10.1016\/j.cardfail.2025.02.014"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Oikonomou EK, Sangha V, Shankar SV, Coppi A, Krumholz HM, Nasir K, et al. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. <i>Eur Heart J<\/i> 2025; 46: 3651\u20133662, doi:10.1093\/eurheartj\/ehaf450.","DOI":"10.1093\/eurheartj\/ehaf450"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Salimi Y, Shiri I, Mansouri Z, Sanaat A, Hajianfar G, Hervier E, et al. Artificial intelligence-based cardiac transthyretin amyloidosis detection and scoring in scintigraphy imaging: Multi-tracer, multi-scanner, and multi-center development and evaluation study. <i>Eur J Nucl Med Mol Imaging<\/i> 2025; 52: 2513\u20132528, doi:10.1007\/s00259-025-07117-1.","DOI":"10.1007\/s00259-025-07117-1"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Goto S, Mahara K, Beussink-Nelson L, Ikura H, Katsumata Y, Endo J, et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. <i>Nat Commun<\/i> 2021; 12: 2726, doi:10.1038\/s41467-021-22877-8.","DOI":"10.1038\/s41467-021-22877-8"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/10\/8_CR-26-0095\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:30:00Z","timestamp":1791603000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/10\/8_CR-26-0095\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-26-0095","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"CR-26-0095"}}